Kyle Groshans
Psychiatric/Mental Health · Syracuse, NYNPI 1336751627
Payments from drug & device makers
Across 578 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Vanda Pharmaceuticals Inc.$707
- Takeda Pharmaceuticals U.S.A., Inc.$667
- Alkermes, Inc.$648
- Lundbeck LLC$646
- plus $4K from 22 others
What the payments were for
- Food & beverage$9,33497%
- Education$3303%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 87 | $1,478 |
| AbbVie(2 entities) | 110 | $1,370 |
| Vanda Pharmaceuticals Inc. | 28 | $707 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $667 |
| Alkermes, Inc. | 41 | $648 |
| Lundbeck LLC | 43 | $646 |
| Sunovion Pharmaceuticals Inc. | 39 | $629 |
| Teva Pharmaceuticals USA, Inc. | 25 | $574 |
| Neurocrine Biosciences, Inc. | 23 | $433 |
| Johnson & Johnson | 21 | $384 |
| Otsuka America Pharmaceutical, Inc. | 18 | $338 |
| Jazz Pharmaceuticals Inc. | 14 | $273 |
| E.r. Squibb & Sons, L.L.C. | 13 | $215 |
| Axsome Therapeutics, Inc. | 16 | $211 |
| Almatica Pharma LLC | 11 | $163 |
| Corium, LLC | 7 | $143 |
| Supernus Pharmaceuticals, Inc. | 7 | $141 |
| Indivior Inc. | 7 | $134 |
| Bausch Health US, LLC | 7 | $127 |
| Biogen | 5 | $103 |
| Braeburn Inc. | 4 | $76 |
| Biohaven Pharmaceuticals, Inc. | 4 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Eisai Inc. | 3 | $40 |
| SK Life Science, Inc. | 1 | $18 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Noven Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$110
How this compares
$9,664 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 36 | $352,160 |
| RexultiBrexpiprazole | 18 | $32,799 |
| CaplytaLumateperone Tosylate | 13 | $20,150 |
| TrintellixVortioxetine Hydrobromide | 16 | $19,281 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $13,848 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 19 | $13,221 |
| Loreev XrLorazepam | 12 | $4,994 |
| Lurasidone Hcl | 15 | $3,810 |
| Lisdexamfetamine Dimesylate | 13 | $3,288 |
| Paliperidone ErPaliperidone | 32 | $2,678 |
| Duloxetine Hcl | 38 | $2,493 |
| Trazodone Hcl | 74 | $1,952 |
| Clonazepam | 77 | $1,529 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 23 | $1,354 |
| Nefazodone Hcl | 12 | $1,241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $433 | $352,16036 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $338 | $32,79918 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,478 | $20,15013 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $667 | $19,28116 claims |
| Axsome Therapeutics, Inc.Auvelity | $211 | $13,84813 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $163 | $5,16534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Syracuse
- Sherie RamsgardSyracuse$52K
- Laneasha EudellSyracuse$15K
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Mary OlsonNew York$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.